NASDAQ:NUVL Nuvalent (NUVL) Stock Price, News & Analysis → Grab Your Free Bitcoin Today! (From Crypto Swap Profits) (Ad) Free NUVL Stock Alerts $75.09 -1.55 (-2.02%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$73.86▼$76.2050-Day Range$73.50▼$88.9952-Week Range$23.09▼$89.39Volume713,785 shsAverage Volume379,396 shsMarket Capitalization$4.81 billionP/E RatioN/ADividend YieldN/APrice Target$81.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Nuvalent alerts: Email Address Nuvalent MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside8.5% Upside$81.50 Price TargetShort InterestBearish22.77% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.40Based on 11 Articles This WeekInsider TradingSelling Shares$8.09 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.96) to ($3.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.71 out of 5 starsMedical Sector856th out of 938 stocksPharmaceutical Preparations Industry387th out of 425 stocks 2.3 Analyst's Opinion Consensus RatingNuvalent has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $81.50, Nuvalent has a forecasted upside of 8.5% from its current price of $75.09.Amount of Analyst CoverageNuvalent has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted22.77% of the float of Nuvalent has been sold short.Short Interest Ratio / Days to CoverNuvalent has a short interest ratio ("days to cover") of 18.3, which indicates bearish sentiment.Change versus previous monthShort interest in Nuvalent has recently increased by 7.80%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuvalent does not currently pay a dividend.Dividend GrowthNuvalent does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NUVL. Previous Next 3.0 News and Social Media Coverage News SentimentNuvalent has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Nuvalent this week, compared to 2 articles on an average week.Search Interest3 people have searched for NUVL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows11 people have added Nuvalent to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nuvalent insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,092,507.00 in company stock.Percentage Held by Insiders14.77% of the stock of Nuvalent is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.26% of the stock of Nuvalent is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nuvalent are expected to decrease in the coming year, from ($2.96) to ($3.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nuvalent is -34.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nuvalent is -34.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuvalent has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Nuvalent Stock (NASDAQ:NUVL)Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Read More NUVL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NUVL Stock News HeadlinesMarch 28, 2024 | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Director Matthew Shair Sells 37,500 SharesMarch 26, 2024 | insidertrades.comNuvalent, Inc. (NASDAQ:NUVL) Insider Darlene Noci Sells 20,000 SharesMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 25, 2024 | finance.yahoo.comChief Development Officer Darlene Noci Sells 20,000 Shares of Nuvalent Inc (NUVL)March 22, 2024 | finance.yahoo.comCompanies Like Nuvalent (NASDAQ:NUVL) Can Afford To Invest In GrowthMarch 22, 2024 | americanbankingnews.comNuvalent, Inc. (NASDAQ:NUVL) Given Average Rating of "Moderate Buy" by BrokeragesMarch 19, 2024 | finance.yahoo.comDirector Emily Conley Sells 13,333 Shares of Nuvalent Inc (NUVL)March 16, 2024 | finance.yahoo.comNUVL Apr 2024 100.000 callMarch 28, 2024 | Behind the Markets (Ad)[BUY ALERT] Our #1 A.I. Stock for MarchIt's the one AI stock nobody is talking about. Cathy Wood just bought 11 million shares of it.March 5, 2024 | prnewswire.comNuvalent to Present New Preclinical Data on HER2-Selective Inhibitor, NVL-330, and ROS1-Selective Inhibitor, zidesamtinib, at AACR Annual Meeting 2024February 29, 2024 | finance.yahoo.comNuvalent Inc (NUVL) Reports Full Year and Q4 2023 Financial Results with Strong Cash Position ...February 27, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Nuvalent (NUVL) and Arcutis Biotherapeutics (ARQT)February 27, 2024 | benzinga.comRecap: Nuvalent Q4 EarningsFebruary 27, 2024 | finanznachrichten.deNuvalent, Inc.: Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520February 27, 2024 | markets.businessinsider.comNuvalent, Inc. Q4 Loss increases, misses estimatesFebruary 27, 2024 | msn.comNuvalent lung cancer candidate gets FDA breakthrough therapy statusFebruary 27, 2024 | finance.yahoo.comNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | prnewswire.comNuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 27, 2024 | prnewswire.comNuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520February 26, 2024 | seekingalpha.comNuvalent: Pivotal NSCLC Programs Progressing With Additional Data In 2024February 24, 2024 | msn.comBaird Initiates Coverage of Nuvalent (NUVL) with Outperform RecommendationFebruary 23, 2024 | msn.comBaird starts Nuvalent at outperform, cites potential of lead assetsFebruary 23, 2024 | msn.comNuvalent (NUVL) Price Target Increased by 9.19% to 89.47February 20, 2024 | finance.yahoo.comNUVL Jul 2024 90.000 callFebruary 20, 2024 | finance.yahoo.comNUVL Apr 2024 105.000 callFebruary 20, 2024 | finance.yahoo.comNUVL Apr 2024 80.000 putFebruary 16, 2024 | finance.yahoo.comNUVL Mar 2024 100.000 callSee More Headlines Receive NUVL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nuvalent and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NUVL CUSIPN/A CIK1861560 Webwww.nuvalent.com Phone857-357-7000FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Stock Price Target$81.50 High Stock Price Target$105.00 Low Stock Price Target$42.00 Potential Upside/Downside+8.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-126,220,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-25.74% Return on Assets-24.50% Debt Debt-to-Equity RatioN/A Current Ratio22.83 Quick Ratio22.83 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.94 per share Price / Book6.86Miscellaneous Outstanding Shares64,070,000Free Float54,605,000Market Cap$4.81 billion OptionableOptionable Beta1.36 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. James R. Porter Ph.D. (Age 48)CEO, President & Director Comp: $998.02kProf. Matthew D. Shair Ph.D. (Age 55)Founder, Head of Scientific Advisory Board & Director Comp: $235kMs. Alex Balcom CPA (Age 39)M.B.A., CFO & Treasurer Comp: $654.22kDr. Christopher D. Turner M.D. (Age 55)Chief Medical Officer Comp: $714.26kDr. Benjamin Lane Ph.D.Senior Vice President of Technical OperationsMs. Deborah Ann Miller J.D. (Age 48)Ph.D., Chief Legal Officer & Secretary Comp: $595.96kMr. Matthew MetivierSenior Vice President of Human ResourcesMs. Darlene Noci (Age 46)Chief Development Officer Mr. Henry Pelish Ph.D.Senior Vice President of Drug DiscoveryMr. John Soglia Ph.D.Senior Vice President of Translational DevelopmentMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLOrganon & Co.NYSE:OGNBiohavenNYSE:BHVNBridgeBio PharmaNASDAQ:BBIOAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsMatthew ShairSold 37,500 sharesTotal: $2.88 M ($76.77/share)Darlene NociSold 20,000 sharesTotal: $1.55 M ($77.51/share)Vanguard Group Inc.Bought 1,205,668 shares on 3/11/2024Ownership: 5.333%Wellington Management Group LLPSold 542,965 shares on 3/5/2024Ownership: 1.618%Goldman Sachs Group Inc.Bought 138,524 shares on 3/1/2024Ownership: 0.349%View All Insider TransactionsView All Institutional Transactions NUVL Stock Analysis - Frequently Asked Questions Should I buy or sell Nuvalent stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nuvalent in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NUVL shares. View NUVL analyst ratings or view top-rated stocks. What is Nuvalent's stock price target for 2024? 9 Wall Street analysts have issued 1 year price targets for Nuvalent's stock. Their NUVL share price targets range from $42.00 to $105.00. On average, they anticipate the company's share price to reach $81.50 in the next twelve months. This suggests a possible upside of 8.5% from the stock's current price. View analysts price targets for NUVL or view top-rated stocks among Wall Street analysts. How have NUVL shares performed in 2024? Nuvalent's stock was trading at $73.59 on January 1st, 2024. Since then, NUVL shares have increased by 2.0% and is now trading at $75.09. View the best growth stocks for 2024 here. When is Nuvalent's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our NUVL earnings forecast. How were Nuvalent's earnings last quarter? Nuvalent, Inc. (NASDAQ:NUVL) posted its earnings results on Tuesday, February, 27th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.60) by $0.02. What ETFs hold Nuvalent's stock? ETFs with the largest weight of Nuvalent (NASDAQ:NUVL) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR) and Virtus LifeSci Biotech Clinical Trials ETF (BBC).Invesco DWA SmallCap Momentum ETF (DWAS). When did Nuvalent IPO? Nuvalent (NUVL) raised $151 million in an IPO on Thursday, July 29th 2021. The company issued 8,900,000 shares at a price of $16.00-$18.00 per share. Who are Nuvalent's major shareholders? Nuvalent's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (5.33%), Vanguard Group Inc. (5.33%), Perceptive Advisors LLC (4.66%), Commodore Capital LP (2.13%), Boxer Capital LLC (1.79%) and Price T Rowe Associates Inc. MD (1.77%). Insiders that own company stock include Alexandra Balcom, Anna Protopapas, Christopher Durant Turner, Darlene Noci, Deborah Ann Miller and Matthew Shair. View institutional ownership trends. How do I buy shares of Nuvalent? Shares of NUVL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NUVL) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingFed launches fourth dollar overhaulStansberry Research“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.